Virpax Pharmaceuticals (VRPX) News Today $0.63 +0.01 (+2.11%) (As of 11:12 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public OfferingNovember 18 at 10:23 AM | globenewswire.comVirpax Pharmaceuticals Announces $5M Public OfferingNovember 16, 2024 | markets.businessinsider.comVirpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsNovember 15, 2024 | businesswire.comVirpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsNovember 13, 2024 | finance.yahoo.comAdial Pharmaceuticals appoints Shah as Chief Financial OfficerNovember 6, 2024 | markets.businessinsider.comVirpax Pharmaceuticals (NASDAQ:VRPX) Stock, Short Interest ReportOctober 2, 2024 | benzinga.comVirpax Pharmaceuticals (NASDAQ:VRPX) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comVirpax Pharmaceuticals’ Promising Outlook: Buy Rating Justified by Strategic Financial Management and Innovative Pain Management PipelineAugust 16, 2024 | markets.businessinsider.comVirpax Pharmaceuticals to Present at Sidoti August Virtual Investor ConferenceAugust 13, 2024 | msn.comVirpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent DevelopmentsAugust 13, 2024 | finance.yahoo.comVRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q2 2024August 13, 2024 | investorplace.com3 Penny Stocks to Watch Now, 7/23/24July 23, 2024 | msn.comMaxim Group Upgrades Virpax Pharmaceuticals (VRPX)July 20, 2024 | msn.comWhy Is Virpax Pharmaceuticals (VRPX) Stock Up 98% Today?July 10, 2024 | investorplace.comWhy Is Virpax Pharmaceuticals (VRPX) Stock Up 97% Today?July 8, 2024 | investorplace.comVirpax® Pharmaceuticals to Present at 2024 BIO International ConventionMay 29, 2024 | businesswire.comMaxim Group Downgrades Virpax Pharmaceuticals (VRPX)May 23, 2024 | msn.comVirpax Pharmaceuticals sets terms for $2.25 million offeringMay 18, 2024 | uk.investing.comVirpax Pharmaceuticals Inc.May 16, 2024 | wsj.comVirpax Pharmaceuticals Shares Hit All-Time Low After Equity SaleMay 15, 2024 | marketwatch.comWhy Is Virpax Pharmaceuticals (VRPX) Stock Down 61% Today?May 15, 2024 | investorplace.comVirpax Announces Pricing of $2.25 Million Public OfferingMay 15, 2024 | businesswire.comVRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q1 2024May 14, 2024 | investorplace.comVirpax Pharmaceuticals Reports 2024 First Quarter Results and Recent DevelopmentsMay 13, 2024 | businesswire.comVirpax Pharmaceuticals' Probudur Shows Promising Results in Pain Management StudyMay 8, 2024 | msn.comVirpax Announces Results of Maximum Tolerated Dose Study for Probudur™April 30, 2024 | businesswire.comVRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023April 24, 2024 | investorplace.comVirpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management SolutionsApril 2, 2024 | msn.comVirpax Pharmaceuticals Reports 2023 Year-End ResultsMarch 26, 2024 | businesswire.comTrading was temporarily halted for "VRPX" at 09:03 AM with a stated reason of "LULD pause."March 1, 2024 | marketbeat.comTrading was temporarily halted for "VRPX" at 07:02 PM with a stated reason of "News pending."March 1, 2024 | marketbeat.comVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid PriceFebruary 27, 2024 | finance.yahoo.comVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid PriceFebruary 27, 2024 | businesswire.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | businesswire.comVirpax Pharmaceuticals Reports Promising Results in Probudur Pilot StudyFebruary 12, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)February 9, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)February 7, 2024 | markets.businessinsider.comVirpax Pharmaceuticals Inc (VRPX)January 23, 2024 | investing.comVirpax Pharmaceuticals shareholders okay reverse stock splitDecember 29, 2023 | msn.comTitan Pharmaceuticals to conduct 1-for-20 reverse stock splitDecember 28, 2023 | msn.comVRPX Virpax Pharmaceuticals, Inc.November 22, 2023 | seekingalpha.comPromising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax PharmaceuticalsNovember 18, 2023 | markets.businessinsider.comVirpax Pharmaceuticals gets non-compliance notice from NasdaqNovember 17, 2023 | msn.comVirpax Pharmaceuticals CEO and Chairman resigns on ongoing litigationNovember 17, 2023 | msn.comVirpax Pharmaceuticals Announces Leadership TransitionNovember 17, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q FilingNovember 17, 2023 | finance.yahoo.comVirpax Pharmaceuticals GAAP EPS of -$0.51November 15, 2023 | msn.comVirpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA ReviewOctober 31, 2023 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)September 28, 2023 | markets.businessinsider.comVirpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation StudiesSeptember 27, 2023 | finance.yahoo.com Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin VRPX Media Mentions By Week VRPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRPX News Sentiment▼0.430.47▲Average Medical News Sentiment VRPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRPX Articles This Week▼30▲VRPX Articles Average Week Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TLPH News SNSE News AWH News TSBX News IPA News CDT News PHXM News INDP News KPRX News TRIB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRPX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
